Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call

Group 1 - The article discusses the performance of Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), noting that despite a previous "Sell" rating given in October, the stock price has increased significantly over the past six months [2] - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts to watch, buy and sell ratings, and forecasts for major pharmaceutical companies [2] - The article emphasizes the importance of detailed financial models and market analysis in making informed investment decisions within the biotech sector [2] Group 2 - The author, Edmund Ingham, has over five years of experience in covering biotech, healthcare, and pharma, having compiled detailed reports on more than 1,000 companies [2] - The article does not contain any personal investment positions or plans to initiate such positions in the companies mentioned, indicating an objective analysis [3] - Seeking Alpha clarifies that past performance is not indicative of future results and that the views expressed may not represent the platform as a whole [4]